Class / Patent application number | Description | Number of patent applications / Date published |
514150200 | Albumin or derivative affecting or utilizing | 76 |
20100273711 | INDIVIDUALIZED CANCER TREATMENTS - Provided herein are methods for the use of gene expression profiling to determine whether an individual afflicted with cancer will respond to a therapy, and in particular to therapeutic agents such as platinum-based agents and antimetabolite agents. Methods for the treatment of individuals with the therapeutic agents are also provided. Methods of predicting the efficacy of cancer therapeutic agents such as platinum-based and antimetabolite therapeutic agents are also provided. Kits including gene chips and instructions for predicting responsiveness are also provided. | 10-28-2010 |
20100286048 | Albumin Fusion Proteins - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention. | 11-11-2010 |
20100317586 | METHOD FOR TOPICAL TREATMENT OF EYE DISEASE AND COMPOSITION AND DEVICE FOR SAID TREATMENT - A method for the prevention or treatment of an eye disease, which includes topically applying to a patient in need of the treatment an aqueous ophthalmic composition which includes N-acetylcarnosine, a N-acetylcarnosine derivative or a pharmacologically acceptable salt of N-acetylcarnosine, in combination with an amount of a cellulose compound or a pharmacologically acceptable salt which is effective to increase intraocular absorption of N-acetylcarnosine or L-carnosine or a derivative of L-carnosine, such as anserine or balenine, in the aqueous humor. A hydrophilic hydrogel contact lens and an ocular polymer insert for topical application of an ophthalmic composition to the eyes of a patient is also disclosed, with the lens or insert containing N-acetylcarnosine, a N-acetylcarnosine derivative or a pharmacologically acceptable salt of N-acetylcarnosine. | 12-16-2010 |
20110015130 | Polypeptides Selective for alphavbeta3 Integrin Conjugated With a Variant Of Human Serum Albumin (HSA) And Pharmaceutical Uses Thereof - The invention generally relates to fusion proteins comprising a rhodostomin variant having an RGD motif variant | 01-20-2011 |
20110021431 | Methods And Compositions For Medical Articles Produced From Proteinaceous Compounds - The invention disclosed herein provides compositions and methods for biocompatible biomaterials with improved control of microorganisms, improved biocompatibility, lower toxicity, and reduce vCJD transmission potential. These combined benefits cascade to provide improved efficacy, improved patient compliance and improved performance, while limiting clinical complications in treatment. | 01-27-2011 |
20110039781 | Treatment of Conditions Related to Cecal Ligation Shock - Techniques, methods and lavages are disclosed for prevention or treatment of shock, particularly cecal ligation or cecal inoculation shock, by administering a specific therapeutic agent, which is able to use smaller volumes of reagent to achieve partial to complete inhibition, than other previously described techniques. The agent includes a combination of enzyme inhibitor, cytotoxic lipid binding protein, and antibiotic. | 02-17-2011 |
20110065642 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE AND/OR CORNEAL AND CONJUNCTIVAL LESION - The present invention provides a pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion which comprises a recombinant human serum albumin produced by a recombinant yeast obtained by transforming a yeast with a gene for human serum albumin. Further, the present invention provides a method for the treatment of dry eye and/or corneal and conjunctival lesion, which comprises administering an effective amount of a recombinant human serum albumin produced by a recombinant yeast obtained by transforming a yeast with a gene for human serum albumin to a subject in need of the treatment of eye and/or corneal and conjunctival lesion. | 03-17-2011 |
20110112031 | OPTIMIZED DENGUE VIRUS ENTRY INHIBITORY PEPTIDE (DN81) - The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds. | 05-12-2011 |
20110124566 | ANTI-TUMOR FIBRILLAR HUMAN SERUM ALBUMIN METHODS AND COMPOSITIONS - Fibrillar human serum albumin was shown to be effective in the treatment of various types of cancers. Methods and compositions are disclosed for using fibrillar human serum albumin as a medicament to treat subjects having cancer. | 05-26-2011 |
20110166072 | Polypeptides Selective for avB3 Integrin, Including Pegylated Polypeptides, And Pharmaceutical Uses Thereof - The invention provides disintegrin variants, and more specifically to disintegrin variants which are selective αvβ3 integrin antagonists for treatment and prevention of αvβ3 integrin-associated diseases. The present invention also relates to pegylated proteins, including proteins comprising a disintegrin variant having an RGD motif variant | 07-07-2011 |
20110230411 | Albumin fibers and fabrics and methods of generating and using same - Provided are method of generating a fiber from a globular protein such as albumin. Also provided are albumin fibers and fabrics and methods of using same for bonding a damaged tissue or for ex vivo or in vivo formation of a tissue. | 09-22-2011 |
20110245177 | METHOD FOR TOPICAL TREATMENT OF EYE DISEASE AND COMPOSITION AND DEVICE FOR SAID TREATMENT - A method for the prevention or treatment of an eye disease, which includes topically applying to a patient in need of the treatment an aqueous ophthalmic composition which includes N-acetylcarnosine, a N-acetylcarnosine derivative or a pharmacologically acceptable salt of N-acetylcarnosine, in combination with an amount of a cellulose compound or a pharmacologically acceptable salt which is effective to increase intraocular absorption of N-acetylcarnosine or L-carnosine or a derivative of L-carnosine, such as anserine or balenine, in the aqueous humor. A hydrophilic hydrogel contact lens and an ocular polymer insert for topical application of an ophthalmic composition to the eyes of a patient is also disclosed, with the lens or insert containing N-acetylcarnosine, a N-acetylcarnosine derivative or a pharmacologically acceptable salt of N-acetylcarnosine. | 10-06-2011 |
20120004177 | COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS - The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell. | 01-05-2012 |
20120010144 | Peg-albumin composition having at least one protected thiol region as a platform for medications - This composition comprises a polyethylene glycol-albumin composition having at least one protected thiol region wherein the composition comprises PEG-AlbCys34 with Cys-34 preserved as a thiol. The albumin is linked to medications such as, antioxidants with a reduced sulfhydryl group through the Cys 34 residing on the albumin. The compositions are useful in treating patients. | 01-12-2012 |
20120046231 | COMPOSITION AND PROCESS FOR SYNTHESIZING POLYMERIZED HUMAN SERUM ALBUMIN FOR APPLICATIONS IN TRANSFUSION MEDICINE - Described herein is a composition and process for synthesizing a human serum albumin (HSA) based plasma replacement composition that includes a polymerized HSA (PolyHSA) that is chemically stabilized by the reduction of Schiff bases. The PolyHSA may have a molecular weight of at least about 100 kDa and may optionally have a cross-linker to HSA molar ratio of at least about 10:1. The PolyHSA composition is useful for restoring a subject's circulatory volume. | 02-23-2012 |
20120101041 | POLYIONIC DENDRIMER AND HYDROGEL COMPRISING SAME - Provided is a hydrogel which comprises water as the main component at a high water content and has mechanical strength suitable for practical use and which exhibits high transparency and self-healing and shape-retaining properties. Also provided are both a material for the hydrogel and a novel polyionic dendrimer. A polyionic dendrimer which comprises a hydrophilic linear polymer as the core and polyester dendrons attached to both terminals of the linear polymer and in which cationic groups are bonded to the surfaces of the dendrons, said cationic groups being selected from the group consisting of guanidine group, thiourea group, and isothiourea group; a material for a hydrogel, which comprises the polyionic dendrimer and clay; and a hydrogel prepared using the material. | 04-26-2012 |
20120178694 | Modified Compstatin With Peptide Backbone And C-Terminal Modifications - Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs having a constrained backbone at position 8 (glycine) and, optionally, specific substitutions for threonine at position 13. | 07-12-2012 |
20120220530 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 08-30-2012 |
20120245089 | USE OF THE SPARC MICROENVIRONMENT SIGNATURE IN THE TREATMENT OF CANCER - The invention provides multiparametric anti-SPARC antibody-based techniques for predicting the response to therapy, including chemotherapy, radiotherapy, surgical therapy and combination therapies | 09-27-2012 |
20120245090 | METHOD FOR SCREENING AN AGENT BEING USEFUL FOR THE TREATMENT OF DRY EYE AND / OR CORNEAL AND CONJUNCTIVAL LESION AND PHARMACEUTICAL COMPOSITION OBTAINED BY THE METHOD - The present invention provides a method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion of dry eye severity level 3 or more according to the report of the International Dry Eye WorkShop (DEWS Report) (2007) and a pharmaceutical composition comprising the agent. The present invention further provides a method for the treatment of dry eye and/or corneal and conjunctival lesion of dry eye severity level 3 or more according to DEWS Report (2007) using the agent. | 09-27-2012 |
20120252732 | ALBUMIN FUSION PROTEINS - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 10-04-2012 |
20120309682 | SUPPRESSION OF CANCER METASTASIS - Methods are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis. Compositions of fibrillar proteins as anti-cancer metastasis therapeutics and methods of use thereof are provided herein. | 12-06-2012 |
20120316117 | PROCESS TO PRODUCE FIBRILLAR PROTEINS AND METHOD OF TREATMENT USING FIBRILLAR PROTEINS - A method for inhibiting survival of cancer cells in a subject is disclosed. The method comprises administering to a subject in need thereof a therapeutically effective amount of fibrillar albumin. The preparation of the fibrillar albumin comprises: (i) forming a solution comprising an isolated and/or purified globular albumin; (ii) adding a detergent to the solution containing the isolated and/or purified globular albumin, wherein the detergent is one selected from the group consisting of sodium dodecyl sulfate (SDS) and n-tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate; (iii) applying the solution to a molecular sizing column with a pore size that permits separation of a protein with a molecular weight of at least about 70 kDa so as to promote column-induced formation of the fibrillar albumin from the isolated and/or purified globular albumin; and (iv) eluting the fibrillar albumin from the column, wherein the eluted albumin has a fibrillar structure. | 12-13-2012 |
20120322739 | Albumin Variants - The invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 12-20-2012 |
20130012443 | METHODS OF TREATMENT OF CENTRAL NERVOUS SYSTEM HEMORRHAGE USING PROTOPORPHYRIN IX-FE COMPOUNDS - Described herein are methods and compositions relating to treatment of tissue damage resulting from a central nervous system (CNS) hemorrhage with a protoporphyrin IX-Fe compound. | 01-10-2013 |
20130053322 | HSA-RELATED COMPOSITIONS AND METHODS OF USE - Provided are human serum albumin (HSA) compositions with improved properties over native HSA. | 02-28-2013 |
20130059785 | Gene and Polypeptide Sequences - The present invention provides a polypeptide comprising (i) a leader sequence, the leader sequence comprising a (a) secretion pre sequence, and (b) the following motif: | 03-07-2013 |
20130102536 | COMPOSITIONS AND METHODS FOR MODULATING TOLL-LIKE RECEPTOR 2 ACTIVATION - A method of promoting hair growth of a subject includes administering to follicle cells of the subject a therapeutically effective amount of a TLR2 agonist that promotes TLR2 activation and hair growth of the subject. | 04-25-2013 |
20130123183 | Anti-tumor Fibrillar Human Serum Albumin Methods and Compositions - Fibrillar human serum albumin was shown to be effective in the treatment of various types of cancers. Methods and compositions are disclosed for using fibrillar human serum albumin as a medicament to treat subjects having cancer. | 05-16-2013 |
20130143819 | FERRIMANNITOL-OVALBUMIN TABLET COMPOSITION - The invention refers to an oral pharmaceutical tableted dosage form which comprises a mixture of: a) granules comprising ferrimannitol-ovalbumin (FMOA) and at least an intragranular pharmaceutical acceptable excipient including a binder; and b) extragranular pharmaceutical excipients including a filler and a binder; which may be obtained by wet-granulation and compression. | 06-06-2013 |
20130172260 | PREVENTION OF INDWELLING DEVICE RELATED INFECTION: COMPOSITION AND METHODS - Catheters used for medical treatment, e.g., hemodialysis are filled with a locking solution, usually heparin between treatments. To prevent infections, antimicrobial or antibiotic substances have been used as locking solution alone or in combination with antithrombotic substances. It has been found that these locking solutions are rapidly washed out from the catheter tip. The invention describes a thixotropic gel that can be used as locking solution. Beneficial substances, e.g., antimicrobial or antibiotic substances can be added to the gel. A preferred antimicrobial substance is taurolidine alone or in combination with salicylic acid or one of its salts. | 07-04-2013 |
20130172261 | USE OF 2 ANTI-SPARC ANTIBODIES TO PREDICT RESPONSE TO CHEMOTHERAPY - The invention provides anti-SPARC antibody-based techniques for predicting a response to chemotherapy. | 07-04-2013 |
20130178422 | SPARC AND METHODS OF USE THEREOF - The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor. | 07-11-2013 |
20130178423 | SPARC AND METHODS OF USE THEREOF - The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor. | 07-11-2013 |
20130203675 | ASYMMETRIC BIOFUNCTIONAL SILYL MONOMERS AND PARTICLES THEREOF AS PRODRUGS AND DELIVERY VEHICLES FOR PHARMACEUTICAL, CHEMICAL AND BIOLOGICAL AGENTS - Asymmetric bifunctional silyl (ABS) monomers comprising covalently linked pharmaceutical, chemical and biological agents are described. These agents can also be covalently bound via the silyl group to delivery vehicles for delivering the agents to desired targets or areas. Also described are delivery vehicles which contain ABS monomers comprising covalently linked agents and to vehicles that are covalently linked to the ABS monomers. The silyl modifications described herein can modify properties of the agents and vehicles, thereby providing desired solubility, stability, hydrophobicity and targeting. | 08-08-2013 |
20130225496 | Albumin Variants - The invention relates to variants of albumin. The invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of preparing the variants and to methods of using the variants. | 08-29-2013 |
20130231287 | PEGYLATED ALBUMIN POLYMERS AND USES THEREOF - The present invention provides an albumin polymer and a process of making an albumin polymer, the process comprising breaking instrinsic disulfide bridges in albumin with a reducing agent and crosslinking inter- and intra-molecular disulfide bridges so as to form the polymer. The present invention also provides PEGylated albumin polymers and methods of making PEGylated albumin polymers, the methods comprising polymerizing albumin by crosslinking inter- and intra-molecular disulfide bridges, and PEGylating the albumin polymer. The present invention further provides a pharmaceutical composition useful as a blood plasma expander, blood substitute or for drug delivery, and methods of treating blood loss in a subject and of delivering drugs to a subject's tissue, the pharmaceutical composition comprising a therapeutically effective amount of the PEGylated albumin polymer. | 09-05-2013 |
20130244940 | DESIGNED REPEAT PROTEINS BINDING TO SERUM ALBUMIN - New designed repeat proteins with binding specificity for serum albumin are described, as well as nucleic acids encoding such serum albumin binding proteins, pharmaceutical compositions comprising such proteins, the use of such proteins to modify the pharmacokinetics of therapeutic relevant polypeptides and the use of such proteins in the treatment of diseases. The repeat proteins of the invention have a substantially increased half-life in plasma compared to proteins not binding serum albumin. | 09-19-2013 |
20130252897 | Methods and Compositions Regarding Polychalcogenide Compositions - The present invention concerns the use of polychalcogenide compositions on cells, tissue, organs, and organisms to enhance their survivability. It includes compositions, compounds, methods, articles of manufacture and apparatuses for enhancing survivability and for protecting them from or treating them for injury or damage. In specific embodiments, there are also therapeutic methods and apparatuses for hypoxic/ischemic injury, organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the polychalcogenide compositions described. | 09-26-2013 |
20130261061 | METHOD OF ENHANCING EFFICACY OF BLOOD TRANSFUSIONS - A method of improving the efficacy of a blood transfusion into a subject is provided comprising administering a composition comprising an EAF PEGylated-blood protein into the subject, prior to, during, or subsequent to the blood transfusion. | 10-03-2013 |
20130281376 | SPARC MICROENVIRONMENT SIGNATURE, PLASMA SPARC, AND LDH AS PROGNOSTIC BIOMARKERS IN THE TREATMENT OF CANCER - The invention provides multiparametric anti-SPARC antibody-based techniques for treating cancers as well as determining prognosis and predicting the response to therapy, including chemotherapy, radiotherapy, surgical therapy and combination therapies. | 10-24-2013 |
20130281377 | TREATING MULTIPLE MYELOMA - This document relates to methods and materials for treating multiple myeloma. For example, methods and materials for using albumin-bound paclitaxel composition (e.g., Abraxane®, a paclitaxel albumin-stabilized nanoparticle formulation) to treat multiple myeloma are provided. | 10-24-2013 |
20130296246 | COMPOSITION - The invention relates to a composition comprising albumin and a therapeutic agent, particularly a gene therapy vector. The composition is useful in the treatment of glioma. | 11-07-2013 |
20130316952 | Non-Natural Consensus Albumin Binding Domains - Non-natural albumin binding domains, polynucleotides encoding thereof and methods of making and using these domains and polynucleotides are useful in controlling the half-life of therapeutic molecules for patients. | 11-28-2013 |
20130338074 | FUSION PROTEIN COMPRISING ALBUMIN AND RETINOL-BINDING PROTEIN - There is provided a fusion protein comprising albumin and retinol-binding protein, which can be used for preventing or treating fibrotic diseases. The fusion protein, in which albumin and a retinol-binding protein (RBP) are bound together, induces the formation of cytoplasmic lipid droplets in stellate cells and returns the shape of activated stellate cells to the previous shape thereof before activation. Therefore, the fusion protein can be effectively used in preventing or treating fibrotic diseases occurring in the liver, pancreas, lungs, or other organs. | 12-19-2013 |
20140051635 | COMBINATION THERAPY FOR TREATMENT OF CANCER - The present invention relates to methods and compositions for treating cancer. Some embodiments include methods comprising increasing expression of a nucleic acid encoding secreted protein acidic and rich in cysteine (SPARC) protein or SPARC protein or the level or activity of SPARC protein and administering a chemotherapeutic agent to a subject in need thereof. | 02-20-2014 |
20140051636 | BIOLOGICALLY ACTIVE COMPLEX AND ITS PREPARATION - A biologically active complex comprising either a polypeptide having the sequence of a variant of a naturally occurring protein, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein; or a peptide of up to 50 amino acids, for instance a fragment of the naturally occurring protein or a variant thereof; and a pharmaceutically acceptable salt of a fatty acid or lipid. The complexes of the invention demonstrate a novel mode of action, that gives rise to opportunities for the development of further active agents and screening methods. | 02-20-2014 |
20140066378 | Multivalent Heteromultimer Scaffold Design and Constructs - Provided herein are multifunctional heteromultimer proteins. In specific embodiments is a heteromultimer comprising: at least two polypeptide constructs, each polypeptide construct comprising at least one cargo polypeptide attached to a transporter polypeptide, said transporter polypeptides derived from a monomeric native protein such that said monomeric constructs associate to form the heteromultimer and said transporter polypeptides associate to form a quasi-native structure of the monomeric native protein or analog thereof. These therapeutically novel molecules encompass heteromultimers comprising constructs that function as scaffolds for the conjugation or fusion of therapeutic molecular entities (cargo polypeptides) resulting in the creation of bispecific or multivalent molecular species. Provided herein is a method for creation of bispecific or multivalent molecular species. | 03-06-2014 |
20140080760 | COMBINATION THERAPY FOR TREATMENT OF CANCER - The present invention relates to methods and compositions for the treatment of cancer. Some embodiments include methods of treating cancer comprising administering a chemotherapeutic agent associated with albumin, administering a second chemotherapeutic agent; and administering a third chemotherapeutic agent. | 03-20-2014 |
20140128326 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 05-08-2014 |
20140148392 | HSA-Related Compositions And Methods Of Use - Provided are human serum albumin (HSA) compositions with improved properties over native HSA. | 05-29-2014 |
20140162956 | POLYPEPTIDES - The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for treatment or diagnosis of disease in mammals including humans. | 06-12-2014 |
20140213522 | PHARMACEUTICAL COMPOSITION AND METHOD OF PREPARING SAME - An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with β-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method. | 07-31-2014 |
20140221292 | POLYIONIC DENDRIMER AND HYDROGEL COMPRISING SAME - Provided is a hydrogel which comprises water as the main component at a high water content and has mechanical strength suitable for practical use and which exhibits high transparency and self-healing and shape-retaining properties. Also provided are both a material for the hydrogel and a novel polyionic dendrimer. A polyionic dendrimer which comprises a hydrophilic linear polymer as the core and polyester dendrons attached to both terminals of the linear polymer and in which cationic groups are bonded to the surfaces of the dendrons, said cationic groups being selected from the group consisting of guanidine group, thiourea group, and isothiourea group; a material for a hydrogel, which comprises the polyionic dendrimer and clay; and a hydrogel prepared using the material. | 08-07-2014 |
20140315816 | ALBUMIN VARIANTS - The invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 10-23-2014 |
20140315817 | VARIANT SERUM ALBUMIN WITH IMPROVED HALF-LIFE AND OTHER PROPERTIES - The invention provides methods and materials for making and using variant serum albumin amino acid sequences which exhibit improved properties compared to wild type serum albumin sequences. The invention further provides methods and materials for making and using fusion proteins in which the variant serum albumin amino acid sequences are fused to a therapeutic or diagnostic agent, such as a therapeutic protein, or a functional fragment or variant thereof that maintains activity, and exhibits improved properties. | 10-23-2014 |
20140323407 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF - In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. | 10-30-2014 |
20140357567 | METHODS FOR TREATING CANCERS USING ORAL FORMULATIONS OF CYTIDINE ANALOGS - Provided herein are methods for treating subjects having a cancer, such as a relapsed or refractory solid tumor, wherein the method comprises administering to the subject a cytidine analog. In certain of the methods, the cytidine analog is administered alone or in combination with one or more anti-cancer agents. Also provided are methods for using a cytidine analog, to treat diseases and disorders including disorders related to abnormal cell proliferation, hematologic disorders, and immune disorders, among others. In certain of the methods, the cytidine analog is formulated in an oral dosage form and administered orally. | 12-04-2014 |
20150011475 | METHOD FOR SCREENING AN AGENT BEING USEFUL FOR THE TREATMENT OF DRY EYE AND /OR CORNEAL AND CONJUNCTIVAL LESION AND A PHARMACEUTICAL COMPOSITION OBTAINED BY THE METHOD - The present invention provides a method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion of dry eye severity level 3 or more according to the report of the International Dry Eye WorkShop (DEWS Report) (2007) and a pharmaceutical composition comprising the agent. The present invention further provides a method for the treatment of dry eye and/or corneal and conjunctival lesion of dry eye severity level 3 or more according to DEWS Report (2007) using the agent. | 01-08-2015 |
20150025012 | METHODS AND COMPOSITIONS FOR IDENTIFICATION, ASSESSMENT AND TREATMENT OF CANCERS ASSOCIATED WITH HEDGEHOG SIGNALING - Provided herein are methods, assays and kits for evaluating a sample, e.g., a sample obtained from a cancer patient, to detect one or more hedgehog biomarkers and/or one or more cilium markers. Thus, the invention can be used, inter alia, as a means to identify patients likely to benefit from administration of one or more hedgehog inhibitors, alone or in combination with therapeutic agents; to predict a time course of disease or a probability of a significant event in the disease of a cancer patient; to stratify patient populations; and/or to more effectively treat or prevent a cancer or a tumor associated with hedgehog signaling. | 01-22-2015 |
20150080310 | BIOCOMPATIBLE COMPOSITION - A biocompatible composition which comprises crosslinkable serum albumin, crosslinkable serum protein and/or crosslinkable derivatives derived therefrom, and which is polymerizable to give a hydrogel-forming material, is used in a method for the prevention of pathological adhesions. | 03-19-2015 |
20150141342 | BLOOD BORNE miRNA SIGNATURE FOR THE ACCURATE DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA - The differential expression of select miRNA in plasma and bile among patients with PDAC, chronic pancreatitis (CP), and controls were measured. Patients (n=215) with treatment-naïve PDAC (n=77), CP with bile or pancreatic duct pathology (n=67), and controls (n=71) that had been prospectively enrolled in a Pancreatobiliary Disease Biorepository at the time of endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasound (EUS) were identified. Controls were patients with choledocholithiasis but normal pancreata. The sample was separated into training (n=95) and validation (n=120) cohorts to establish and then test the performance of PDAC Signature Panels in diagnosing PDAC. The training cohort (n=95) included age-matched patients with CP and controls. Panels were derived from the differential expression of 10-candidate miRNA in plasma or bile. Differential expression of miR-10b, -155, and -106b in plasma and bile accurately distinguishes individuals with PDAC from those having CP or normal pancreata. | 05-21-2015 |
20150141343 | SPARC AND METHODS OF USE THEREOF - The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor. | 05-21-2015 |
20150297732 | BIODEGRADABLE MICROBEAD COMPRISING ANIONIC POLYMER FOR IMPROVING ADSORPTIVE POWER TO ANTICANCER DRUGS, AND METHOD FOR PREPARING SAME - The present invention relates to a biodegradable microbead having improved adsorptive power to anticancer drugs, to a method for preparing same, and to a method for treating cancer using same. According to the present invention, a rigid bead having excellent adsorptive power to anticancer drugs can be prepared through cross-linking and an amide bond between an albumin and an anionic polymer. Also, the microbead of the present invention is prepared by a biocompatible and biodegradable polymer so as to be safe when applied to the human body. Further, the microbead of the present invention can effectively inhibit the growth of a tumor by effectively blocking a blood vessel which supplies nutrients to a liver tumor, while continuously releasing anticancer drugs which are adsorbed into the surface of the bead. Thus, the present invention can be usefully applied to a chemoembolization of liver cancer. | 10-22-2015 |
20150343025 | METHOD FOR THE PREPARATION OF HUMAN ALBUMIN WITH REDUCED LEVEL OF DISSOLVED OXYGEN - A method prepares a solution of human albumin by reducing dissolved oxygen in a solution of albumin until a concentration of oxygen equal to or less than 0.5 ppm is achieved. A solution of human albumin having a redox state closer to the redox state of the albumin present in human plasma can be achieved. | 12-03-2015 |
20150359810 | METHODS FOR TREATING EPSTEIN-BARR VIRUS (EBV) ASSOCIATED CANCERS USING ORAL FORMULATIONS OF 5-AZACYTIDINE - Provided herein are methods for treating subjects having an EBV-associated cancer, including a relapsed or refractory solid tumor and Burkitt's lymphoma, wherein the method comprises administering to the subject 5-azacytidine. In certain of the methods, 5-azacytidine is administered alone or in combination with one or more anti-cancer agents. In certain of the methods, 5-azacytidine is formulated in an oral dosage form and administered orally. | 12-17-2015 |
20150366932 | METHODS FOR PRODUCING DIKETOPIPERAZINES AND COMPOSITIONS CONTAINING DIKETOPIPERAZINES - Methods of making increased amounts of diketopiperazines (DKP) such as DA-DKP in pharmaceutical compositions of proteins and peptides are disclosed. The disclosure further provides methods of making a DKP, including (1) contacting albumin with an enzyme (such as a dipeptidyl peptidase N (DPP-IV)) that cleaves a pair of N-terminal amino acids from the albumin, and (2 heating the albumin under conditions effective to cause the formation of the DKP. Further, treatment of DKP- and albumin-containing streams to produce improved, higher value, DKP compositions and purified albumin compositions for therapeutic uses is also disclosed. In addition to a first therapeutic DKP composition comprising a low albumin content, a second valuable therapeutic composition is also produced characterized by a high albumin concentration. | 12-24-2015 |
20160051634 | SUPPRESSION OF CANCER METASTASIS - Methods of using fibrillar proteins are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis. | 02-25-2016 |
20160058844 | "Bilirubin Excretion Enhancer" - The purpose of the present invention is to establish a novel therapy method for hyperbilirubinemia and therefore, to provide a bilirubin excretion enhancer. The present invention provides a bilirubin excretion enhancer comprising, as an active ingredient, a serum albumin domain II-like protein comprising a serum albumin subdomain IIA. In one embodiment, the serum albumin subdomain IIA has an amino acid sequence of SEQ ID NO: 1. in one embodiment, the serum albumin domain II-like protein is a serum albumin domain II. In one embodiment, the serum albumin domain II comprises the amino acid sequence of SEQ ID NO: 4. | 03-03-2016 |
20160067210 | USE OF RHODAMINE DYES TO REDUCE ALVEOLAR SURFACE TENSION - Rhodamine dye is delivered to regions of a lung having heterogeneous alveolar flooding by alveolar liquid, thereby lowering the surface tension of the alveolar liquid so as to lessen ventilation injury directly and, by promoting equitable redistribution of the alveolar liquid among the alveoli of the lung, indirectly. The rhodamine dye is delivered with an albumin and/or an exogenous surfactant. Exemplary rhodamine dyes include sulforhodamine B and rhodamine WT. | 03-10-2016 |
20160083436 | Non-Natural Consensus Albumin Binding Domains - Non-natural albumin binding domains, polynucleotides encoding thereof and methods of making and using these domains and polynucleotides are useful in controlling the half-life of therapeutic molecules for patients. | 03-24-2016 |
20160129127 | Development of Soluble Albuminated Curcumin for Application in Cancer Therapy - This invention relates to an albumin-curcumin conjugate for application in cancer therapy, including albumin and curcumin. | 05-12-2016 |
20160158253 | TREATMENT OF PANCREATIC CANCER WITH A COMBINATION OF A HYPOXIA-ACTIVATED PRODRUG AND A TAXANE - Combined administration of a hypoxia-activated prodrug, such as TH-302, a taxane, such as nab-paclitaxel, and a nucleoside analog chemotherapeutic, such as gemcitabine, are efficacious in the treatment of cancer, including pancreatic cancer. | 06-09-2016 |
20160166728 | BIOADHESIVE FOR OCCLUDING VESSELS | 06-16-2016 |
20160200796 | FUSION PROTEIN COMPRISING ALBUMIN AND RETINOL-BINDING PROTEIN | 07-14-2016 |
20190142748 | FORMULATIONS OF CHLORAMBUCIL | 05-16-2019 |